How Often Can You Microneedle? Once a Month, Two Bank Cards Deep

Once every 30 days, three to six sessions, then stop. The clinical study behind the FDA's 2018 classification of microneedling devices treated patients on day 1, day 30 and day 60; a separate 2020 study of an automated pen ran four sessions at four-week intervals in 47 patients. Redness, itching, peeling and tenderness lasted one to three days in 31 percent of subjects in the FDA study. No cleared device carries evidence supporting depths past 1.5 mm, which is roughly two bank cards stacked.

Where the 30-day gap comes from

The gap is set by collagen. Alster and Graham, whose 2018 review in Dermatologic Surgery is the paper most clinicians cite, put the lag between starting treatment and clinically apparent results from dermal collagen production at six to eight weeks, and describe the series as three to six sessions. Their case illustrations use monthly spacing. Thirty days is firmest where it was tested, inside the device trials.

I logged effects at a funeral home in Sheffield, mostly cutting rings off fingers swollen past sliding. A band worn thirty years leaves a groove. The skin over it closes within days of the ring coming off; the groove is still there weeks later. Repair of the surface and repair of the structure run on separate clocks, and microneedling is bought on the slower one.

No trial has established a maintenance interval. The FDA study followed subjects six months past the final session and stopped. Among the 20 people treated with the cleared device, 35 percent improved by one grade on the acne scar scale and 45 percent showed no change. Clinics quote top-ups every three to six months. That is convention, and it should not reach you dressed as data.

Depth is the number that sets the risk

The cleared pen carries 14 needles driven at 7,000 rpm, across 11 depth settings from 0 to 2.5 mm in 0.25 mm steps. FDA's decision summary states that safety and effectiveness above 1.5 mm has not been evaluated. The anatomical studies the file cites explain why: motor and sensory nerves capable of causing impairment run as shallow as 2 mm, shallowest around the eye, and facial arteries no shallower than 3 to 5 mm.

Labelled depths change by region. Forehead, 0.25 to 1.0 mm. Nose, 0.25 to 0.75 mm. Around the orbital rim and never inside it, 0.25 to 0.5 mm. Facial acne scars, up to 1.5 mm. ISO/IEC 7810 sets a bank card at 0.76 mm, so the ceiling beside your eye is thinner than the card in your wallet.

A spiral ring saw carries a guard between blade and finger because the working distance is a fraction of a millimetre, and you stop treating a quarter of a millimetre as a rounding error. The depth dial moves in those increments. Someone running 1.0 mm on your forehead every four weeks is not doing the same procedure at the same frequency as someone running 2.0 mm. Ask for the setting, and ask for it written down.

What one session costs you in days

Numbing comes first, at a published concentration. In the 2020 pen study the whole face was covered with EMLA, 2.5 percent lidocaine and 2.5 percent prilocaine, and the excess wiped off after 30 minutes. FDA's February 2007 advisory followed the deaths of two women, aged 22 and 25, who used compounded creams at higher concentrations before laser hair removal and wrapped the treated skin in plastic. The advice since has been the lowest dose that works, no occlusion, no heat.

What the subject diaries recorded in the FDA study, across 41 people:

| Effect | Share of subjects | How long it lasted | |---|---|---| | Redness, itching, peeling, discomfort, tenderness | 31% | 1 to 3 days | | Dryness | 12% | 1 to 6 days | | Burning | 9% | 1 to 3 days | | Rough skin | 7% | 1 to 2 days | | Tightness | 4% | 1 to 2 days |

In the 2020 study, 94 percent called their redness minimal or absent by day 5, and pain fell below 1 out of 10 by day 3.

The one adverse event judged possibly device-related in the FDA study was striae on a subject's forehead and cheeks, attributed to strong sun soon after treatment, against instructions.

What happens when the gap is too short

No randomised trial has compared two-week and four-week intervals on the face. Every protocol that produced a cleared device ran on 30-day spacing, and the manufacturers had every commercial reason to choose something shorter.

The harms in the literature come from treating too hard or too often. Tram-track scarring, a line of papules following the path of the device, was first reported by Pahwa and colleagues in 2012 and attributed to excessive pressure over a bony prominence. Facial granulomatous reactions are rarer, with roughly a dozen cases in the English-language literature, one of them in a woman who had used an eight-in-one home device with no serum applied at any point. A patient described in JAAD Case Reports in 2021 needed methotrexate at 15 mg weekly for nine months to clear, leaving linear pinpoint scars underneath. Post-inflammatory hyperpigmentation is the commoner outcome and falls hardest on darker skin.

Two weeks puts a needle into tissue still laying down collagen from the last pass. You cannot see that in a mirror, which is the problem.

Microneedling and chemical exfoliation on the same face

People combine the two for texture, and both work by injuring skin. The clearest published spacing rule sits in the exclusion criteria of the trial that created the device category, which turned away anyone who had had microdermabrasion or a glycolic acid treatment in the area within one month, any chemical peel, dermabrasion or fractional laser resurfacing of face or neck within four weeks, topical retinoids within two weeks, or systemic retinoids within six months.

| Treatment | Layer it works on | Interval commonly used | Where that interval comes from | |---|---|---|---| | Microneedling to 1.5 mm | Punctures into the dermis; epidermis reported structurally intact | 30 days | Day 1/30/60 (FDA study); four sessions at four weeks (2020 study) | | Superficial peel (glycolic, salicylic) | Stratum corneum and upper epidermis | 2 to 4 weeks | Trial protocols such as 35% glycolic every two weeks; otherwise convention | | Medium-depth peel (TCA) | Into the papillary dermis | 4 to 6 weeks | Convention |

FDA's decision summary states that lasers and chemical peels carry much higher risk profiles and patient recovery time but may deliver more substantial improvement in acne scars. Stacking a peel onto a microneedling course lengthens the window in which your skin is inflamed, and for Fitzpatrick types IV to VI that window is where pigment problems start.

At home, "how often" is the wrong question

FDA's 2020 guidance draws its line at living skin. A roller that stays above it and claims only exfoliation or a smoother look is not a device at all. The moment it claims to stimulate collagen production, or to treat scars, wrinkles, acne or alopecia, FDA considers it a device, Class II under 21 CFR 878.4430. The cleared pen is prescription-only.

So the answer splits. A roller that genuinely stays above living skin is an exfoliator, and frequency is cosmetic. One that reaches living skin is an unapproved Class II device in your own hand.

Sterility is the larger worry. The cleared cartridge is sterilised with ethylene oxide, validated to ISO 11135-1 at a sterility assurance level of 10⁻⁶, and the handpiece carries a lockout that refuses a cartridge already used once. In the effects room, a blade that had touched a body went into the tray and out. Nothing came back to the drawer on a wipe. CDC's Spaulding classification puts instruments that penetrate soft tissue, hypodermic needles among them, in the critical category, which requires sterilisation rather than disinfection. A bathroom sterilises nothing. A 2021 review in the Journal of Clinical and Aesthetic Dermatology records a woman who spread varicella across her chest and face with a home roller.

The scalp runs on a different clock

The weekly scalp protocol traces to one trial. Dhurat and colleagues, in the International Journal of Trichology in 2013, randomised 100 men with grade III vertex or IV androgenetic alopecia to weekly rolling with a 1.5 mm dermaroller plus 5% minoxidil twice daily, or minoxidil alone. Mean hair count gain at 12 weeks was 91.4 against 22.2, and that result has been repeated as settled fact for over a decade.

In May 2026 the Journal of the American Academy of Dermatology published the first randomised comparison of frequencies: 245 women with Savin grades D3 to D6, assigned to 2% minoxidil alone (83), minoxidil plus monthly microneedling (82), or minoxidil plus microneedling every two weeks (80), over 24 weeks, with a 36-needle cartridge at 500 to 550 µm. Target-area hair counts rose in all three arms with no significant difference between them: 110.5 to 119.0 monthly, 108.2 to 114.3 fortnightly, 104.7 to 114.6 on minoxidil alone.

That does not overturn Dhurat. Different depth, different sex, different minoxidil strength. It does mean anyone quoting "weekly for the scalp" is quoting a protocol the only head-to-head frequency trial failed to support.

What should push the appointment back

The FDA trial's exclusion list is the most specific published statement on who should wait. It ruled out active systemic or local skin disease that might affect wound healing, more than five active inflammatory acne lesions in the treatment area, a history of hypertrophic or keloid scarring, systemic granulomatous disease, active or inactive, such as sarcoidosis or tuberculosis, connective tissue disease such as lupus or dermatomyositis, severe solar elastosis, significant facial trauma within six months, and sensitivity to topical lidocaine. Labelling adds herpes simplex reactivation, so an active cold sore moves the date.

Isotretinoin is the one worth arguing about. Its six-month bar comes from the drug's package insert rather than from trial evidence. The ASDS Guidelines Task Force consensus, published in Dermatologic Surgery in 2017, found insufficient evidence to delay most cutaneous procedures including fractional lasers during or shortly after isotretinoin, with mechanical dermabrasion and full-field ablative resurfacing as the exceptions. Plenty of clinics hold the line anyway. Ask which one your clinician follows and why.

Radiofrequency microneedling is a different device. On 15 October 2025 FDA issued a safety communication about burns, scarring, fat loss, nerve damage and disfigurement reported after its use, and nothing about frequency here transfers to it.

Frequently asked questions

Can you do too much microneedling?

Yes. Consequences of treating too hard or too often include tram-track scarring, first reported in 2012 and attributed to excessive pressure over bone; granulomatous reactions, with roughly a dozen facial cases in the English-language literature; and post-inflammatory hyperpigmentation, which falls hardest on darker skin. Thirty-day intervals and a 1.5 mm ceiling keep you inside tested territory.

How often can you microneedle at home?

FDA's 2020 guidance treats a roller that stays above living skin and claims only exfoliation as a cosmetic rather than a device. Used that way it is exfoliation, at whatever cadence your skin tolerates. Anything reaching living skin functions as an unapproved Class II device, and no home method sterilises it between uses.

How soon can I microneedle again?

Thirty days for a professional session. Your skin will look normal well before that: in the FDA trial, redness and tenderness lasted one to three days in 31 percent of subjects, and in a 2020 study 94 percent reported minimal or absent redness by day 5. Collagen remodelling takes six to eight weeks.

Is it safe to get microneedling every two weeks?

No trial supports fortnightly treatment of the face. Every protocol behind a cleared device used 30-day spacing: day 1, day 30 and day 60 in the FDA study, four sessions at four-week intervals in a 2020 study. At two weeks you are needling tissue still building collagen from the previous session.

How often should you microneedle for hair loss?

The weekly protocol comes from one 2013 trial using a 1.5 mm roller with 5% minoxidil twice daily. A 2026 randomised trial in 245 women compared fortnightly and monthly microneedling at 500 to 550 µm against 2% minoxidil alone, and found no significant difference between any of the three arms at 24 weeks.

Which skin conditions should postpone treatment?

Active skin infection or inflammatory disease, more than five active inflammatory acne lesions in the treatment area, a history of keloid or hypertrophic scarring, sarcoidosis or other granulomatous disease, lupus or dermatomyositis, an active cold sore, and facial trauma within the past six months. Each was an exclusion criterion in the FDA trial.